Anebulo Pharmaceuticals (ANEB) News Today $1.59 +0.07 (+4.61%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Anebulo Pharmaceuticals Advances Cannabis Toxicity SolutionsNovember 16 at 12:05 AM | tipranks.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent UpdatesNovember 13, 2024 | finance.yahoo.comBenchmark maintains Speculative Buy on Anebulo stockOctober 3, 2024 | uk.investing.comAnebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by BenchmarkBenchmark reiterated a "speculative buy" rating and issued a $8.00 price target on shares of Anebulo Pharmaceuticals in a report on Tuesday.October 1, 2024 | marketbeat.comAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent UpdatesSeptember 25, 2024 | finance.yahoo.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 12.8% in AugustAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 14,100 shares, an increase of 12.8% from the August 15th total of 12,500 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 0.2% of the company's shares are sold short.September 16, 2024 | marketbeat.comANEB Anebulo Pharmaceuticals, Inc.July 28, 2024 | seekingalpha.comAnebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic EffectsJuly 22, 2024 | businesswire.comANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024May 15, 2024 | investorplace.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesMay 15, 2024 | finance.yahoo.comGalehead Development to Collaborate With Rivian Automotive on Renewable Energy Project DevelopmentMay 15, 2024 | businesswire.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Drop in Short InterestAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 17,900 shares, a decrease of 10.9% from the April 15th total of 20,100 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily volume of 5,600 shares, the days-to-cover ratio is currently 3.2 days.May 14, 2024 | marketbeat.comAnebulo Pharmaceuticals Inc 214April 17, 2024 | morningstar.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Rises By 308.7%Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 18,800 shares, an increase of 308.7% from the March 15th total of 4,600 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is currently 3.4 days. Approximately 0.2% of the company's shares are short sold.April 10, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)April 2, 2024 | markets.businessinsider.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 10.0%Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 3,300 shares, an increase of 10.0% from the February 14th total of 3,000 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 9,000 shares, the days-to-cover ratio is presently 0.4 days.March 18, 2024 | marketbeat.comMilestone rallies 23% on FDA update for tachycardia drugFebruary 26, 2024 | msn.comAnebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA TrackFebruary 16, 2024 | markets.businessinsider.comNew Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?February 15, 2024 | msn.comSubstance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication DrugFebruary 14, 2024 | msn.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Decline in Short InterestAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,700 shares, a decrease of 18.2% from the January 15th total of 3,300 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 0.2 days.February 14, 2024 | marketbeat.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesFebruary 13, 2024 | finance.yahoo.comAnebulo Pharmaceuticals (ANEB) to Release Quarterly Earnings on ThursdayAnebulo Pharmaceuticals (NASDAQ:ANEB) will be releasing earnings on Thursday, February 8, Yahoo Finance reports.February 7, 2024 | marketbeat.comAnebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and DatesJanuary 20, 2024 | benzinga.comAnebulo Pharmaceuticals, Inc. (ANEB)January 8, 2024 | finance.yahoo.comAnebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80December 17, 2023 | nasdaq.comAnebulo Pharmaceuticals Inc ANEBDecember 9, 2023 | morningstar.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)November 21, 2023 | markets.businessinsider.comBuy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication TreatmentNovember 17, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02November 15, 2023 | msn.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNovember 14, 2023 | finance.yahoo.comHere's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationNovember 6, 2023 | finance.yahoo.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?October 19, 2023 | msn.comDirector at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 SharesOctober 11, 2023 | benzinga.comAnebulo Pharmaceuticals Names Richie Cunningham as CEOOctober 6, 2023 | marketwatch.comAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces New CEOOctober 6, 2023 | finance.yahoo.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | msn.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 25, 2023 | markets.businessinsider.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 23, 2023 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)September 22, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesSeptember 20, 2023 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 18, 2023 | msn.comSubstance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst SaysSeptember 18, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. WainwrightSeptember 18, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesAugust 30, 2023 | finance.yahoo.comAnebulo (ANEB) Gains on Positive FDA Response for ANEB-001August 22, 2023 | finance.yahoo.comAnebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 ApprovalAugust 21, 2023 | markets.businessinsider.comAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionAugust 21, 2023 | finance.yahoo.comWe Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth CarefullyMay 30, 2023 | finance.yahoo.com Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now ANEB Media Mentions By Week ANEB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANEB News Sentiment▼-0.020.56▲Average Medical News Sentiment ANEB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANEB Articles This Week▼50▲ANEB Articles Average Week Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tonix Pharmaceuticals News OptiNose News Sol-Gel Technologies News Atossa Therapeutics News Eledon Pharmaceuticals News Organigram News Tenaya Therapeutics News Checkpoint Therapeutics News Skye Bioscience News Adaptimmune Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANEB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
